LONDON, Nov. 9, 2022 /PRNewswire/ — Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the opening of Smith+Nephew (S+N) Academy Singapore, a major medical education and digital innovation centre covering the Asia-Pacific region today, in the presence of Mr Gan Kim Yong, Minister for Trade and Industry Singapore, Mr Alex Bamford, Deputy British High Commissioner to Singapore, and Smith+Nephew Chief Executive Officer Deepak Nath.
Supporting Smith+Nephew’s purpose of Life Unlimited, the S+N Academy Singapore offers an engaging, immersive and interactive training environment for healthcare professionals from across the region to experience the latest products and technologies, and refine their techniques under the guidance of expert peers.
Deepak Nath, Chief Executive Officer of Smith+Nephew, said:
“We are proud to open S+N Academy Singapore which will provide the right environment and tools for thought leaders to challenge the status quo, refining new technologies and surgical techniques to improve outcomes for patients. We look forward to welcoming healthcare professionals to experience this unique medical innovation experience.”
Myra Eskes, President APAC and Global Service, Smith+Nephew, said:
“Smith+Nephew has a strong and successful business in Asia-Pacific and ambitious growth plans to provide our medical technology to more surgeons and nurses. It is impossible to overstate the importance of education and hands-on experience as we take customers on this journey, and the new Academy will be vital in improving access to the latest innovation to drive better clinical outcomes.”
S+N Academy Singapore includes a state-of-the-art digital operating suite of the future including handheld robotics, 4K arthroscopy towers, surgical navigation tools, live transmission capabilities and touch-screen interfaces. The digital experience is supported by a virtual reality simulation studio, tech-enabled teaching auditorium, and a professional broadcast studio where experts can record and live-stream surgical techniques to educate fellow healthcare professionals across the globe.
S+N Academy Singapore also has fully equipped surgical super-stations for hands-on procedural training across Smith+Nephew’s entire portfolio of orthopaedic reconstruction, trauma, robotics, sports medicine, ear, nose and throat and advanced wound management. It is expected that up to 3500 healthcare providers will attend in-person courses at S+N Academy Singapore every year by 2025, with another 5000 being trained through digital technology.
As an added commitment to medical innovation, S+N Academy Singapore will partner on initiatives within the wider healthcare community, including collaboration with start-ups, early-stage investors and industry partners to support the development of new innovations, and medical institutions to utilise the latest training infrastructure.
Opening courses include peer-to-peer flagship programmes designed specifically for the Asia-Pacific region under the brands INSPIRE™ for Sports Medicine, and ASPIRE™ for Orthopaedic Reconstruction and Robotics. These courses will feature 50 distinguished global faculty and provide peer-to-peer education to 200 healthcare professionals from Asia-Pacific.
Central to Smith+Nephew’s commitment to medical education and improving patient outcomes is providing a comprehensive accessible learning environment tailored to the needs of the healthcare professional. Through the S+N Academy Singapore and other centres in the US and Europe, we are actively transforming the way we educate our customers around the world by surrounding them with leading-edge technology, clinical content and scientific data.
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 18,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.2 billion in 2021. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on Twitter, LinkedIn, Instagram or Facebook.
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID-19, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID-19; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID-19); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew’s most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew’s expectations.
™ Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.
SOURCE Smith & Nephew plc